User:Curtis Bixenstine/Bio460Sandbox

Curtis's User Page

Rose's User Page

Initial Article Assessments from Rglastet

Here are two initial articles that could be improved upon:

Angiogenesis Inhibitor

The article on angiogenesis inhibitors could be modified and improved upon. Much of the basic information is present; however, the section on exogenous drugs requires references. In addition, the section on endogenous inhibitors could benefit from some background information and a completed list of the mechanisms of inhibition (for Meth-1 and Meth-2, canstatin...) Here is a journal article that discusses the role of canstatin in angiogenesis inhibition.

ADAMTS1

The article on ADAMTS1 is a stub-class article that does not include enough information about this particular enzyme in the ADAMTS family of peptidases. Its various roles could also be elaborated upon, including its role in anti-angiogenesis, which is detailed in this article. Rglastet (talk) 22:49, 4 February 2014 (UTC)

Initial Article Assessments from Curtis Bixenstine

Here are two initial articles that could be improved upon:

Angiogenesis Inhibitor

As Rose already pointed out, the article on angiogenesis inhibitors does not meet the criteria for a good article, at this time. The article is well written, but could definitely be organized more thoughtfully. The | Summary section needs to be changed, as it is unclear what the information given is a summary of. Obviously, the drugs section needs to include some references. This is a journal article about the use of antiogenesis inhibitors to treat cancer. It could be used to cite some of the information in the "Drugs" section. Lastly, the two lists are close to being stand-alone lists, and they need to be better introduced in the text.

DLL4

The article on the Delta like ligand 4 protein is a stub and could use some expanding. This article, written by a group of pharmacists working for Regeneron Pharmaceuticals about the role of DLL4 during vascular growth and differentiation, would be a good reference to start expanding this article with. Curtis Bixenstine (talk) 00:19, 5 February 2014 (UTC)

Possible References

Cancer.gov. National Cancer Institute at the National Institutes of Health; 2011 [cited 16 Feb 2014]. Available from: http://www.cancer.gov/cancertopics/factsheet/Therapy/angiogenesis-inhibitors

• includes general definitions
• basic information on angiogenesis and angiogenic inhibitors

Gotink KJ, Verheul HM (March 2010). "Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?". Angiogenesis. 13 (1): 1–14. doi:10.1007/s10456-009-9160-6. PMC 2845892. PMID 20012482.{{cite journal}}: CS1 maint: date and year (link)

• Role of tyrosine kinase inhibitors in anti-angiogenesis therapy

Cook KM, Figg WD (2010). "Angiogenesis inhibitors: current strategies and future prospects". CA Cancer J Clin. 60 (4): 222–43. doi:10.3322/caac.20075. PMC 2919227. PMID 20554717.

Siemann DW (February 2011). "The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents". Cancer Treat. Rev. 37 (1): 63–74. doi:10.1016/j.ctrv.2010.05.001. PMC 2958232. PMID 20570444.{{cite journal}}: CS1 maint: date and year (link)

Nyberg P, Xie L, Kalluri R (May 2005). "Endogenous inhibitors of angiogenesis". Cancer Res. 65 (10): 3967–79. doi:10.1158/0008-5472.CAN-04-2427. PMID 15899784.{{cite journal}}: CS1 maint: date and year (link) CS1 maint: multiple names: authors list (link)

• information on endogenous inhibitors

• specific modes of action of multiple inhibitors derived from ECM or basement membrane protein

Folkman J (2004). "Endogenous angiogenesis inhibitors". APMIS. 112 (7–8): 496–507. doi:10.1111/j.1600-0463.2004.apm11207-0809.x. PMID 15563312.

• mechanisms of cancer treatment for endogenous inhibitors

Cao Y (April 2001). "Endogenous angiogenesis inhibitors and their therapeutic implications". Int. J. Biochem. Cell Biol. 33 (4): 357–69. doi:10.1016/s1357-2725(01)00023-1. PMID 11312106.{{cite journal}}: CS1 maint: date and year (link)

• includes disadvantages of endogenous angiogenic inhibitors and areas of possible improvement

Shih T (November 2006). "Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies". Clinical Therapuetics. 28 (11): 1779–802. doi:10.1016/j.clinthera.2006.11.015. PMID 17212999.{{cite journal}}: CS1 maint: date and year (link)

• includes information on the use of Bevacizumab, an angiogenesis inhibitor used to treat breast cancer, non-small-cell lung cancer, renal cell carcinoma, and other solid malignancies

Verheul HM (June 2007). "Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition". Nature Reviews. Cancer. 7 (6): 475–485. doi:10.1038/nrc2152. PMID 17522716.{{cite journal}}: CS1 maint: date and year (link)

• information on possible disadvantages of using anti-angiogenesis drugs in treating cancer patients; toxicity reports

Hershman DL (October 2013). "Contraindicated use of bevacizumab and toxicity in elderly patients with cancer". Journal of Clinical Oncology. 31 (28): 3592–9. doi:10.1200/JCO.2012.48.4857. PMC 3782151. PMID 24002522.{{cite journal}}: CS1 maint: date and year (link)

• Information on the selected administration of bevacizumab, based on race, age, and medical history

Chen XL (June 2013). "Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis". PLOS ONE. 8 (6): e66721. doi:10.1371/journal.pone.0066721. PMC 3688569. PMID 23818962.{{cite journal}}: CS1 maint: date and year (link)

• more information about the toxicity of bevacizumab,specifically, the mechanism of the drug that could lead to ischemic heart disease

Curtis Bixenstine (talk) 18:21, 20 February 2014 (UTC)

Outline

Title: Angiogenesis Inhibitors

• Introduction

• Include general information

• Mode of Action
• Endogenous Inhibitors

• Explantation of the role of endogenous inhibitors
• Table of endogenous inhibitors

• Exogenous Inhibitors

• Drugs

• bevacizumab
• thalidomide

• http://toxsci.oxfordjournals.org/content/122/1/1.full

• cannabinoids

• Table of exogenous inhibitors
• Diet

• Side Effects

Article Draft

Endogenous Inhibitors

Angiogenesis is regulated by the activity of endogenous stimulators and inhibitors. Unlike exogenous inhibitors, endogenous inhibitors are found in the body naturally and involved in the day-to-day process of regulating blood vessel formation. Endogenous inhibitors are often derived from the extracellular matrix or basement membrane proteins and function by interfering with endothelial cell formation and migration, endothelial tube morphogenesis, and down-regulation of genes expressed in endothelial cells. During tumor growth, the action of angiogenesis stimulators surpasses the control of angiogenesis inhibitors, allowing for unregulated or less regulated blood vessel growth and formation. Endogenous inhibitors are attractive targets for cancer therapy because they are less toxic and less likely to lead to drug resistance than some exogenous inhibitors.

However, the use of endogenous inhibitors has its disadvantages as well. In animal studies, high doses of inhibitors were required to prevent tumor growth and the use of endogenous inhibitors would likely be long-term.

Bevacizumab

Moreover, significant problems have been discovered with the novel antiangiogenic agent bevacizumab, a recombinant humanised monoclonal antibody to the vascular endothelial growth factor that is widely used in cancer treatment. Research on the exact mechanism of toxicity for bevacizumab is still being done, but it appears that the toxicity profiles of these inhibitors reflect the disturbance of growth factor signalling pathways that are important for maintaining homeostasis. However, this novel drug has shown promising results when combined with standard chemotherapy regimens, bevacizumab has been associated with significant improvements compared with chemotherapy alone in the efficacy end points of overall survival, progression-free survival, and response rates in patients with mCRC (all, P < 0.05). Based on these findings, bevacizumab has been denoted a first-rate option for this disease. Combination bevacizumab regimens have been associated with positive clinical activity in breast cancer, non-small-cell lung cancer, renal cell carcinoma, pancreatic cancer, and soft-tissue sarcoma. Because so much research has been done on this drug in the past 5 years, it will be a main topic of discussion in our article.